Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 464-476

  Brien, Gerard L ^a   Valerio, Daria G ^a   Armstrong, Scott A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Chromatin; Epigenome; Histone modification; Targeted therapy

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; CARCINOGENESIS; CHROMATIN; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DRUG EFFECTS; DRUG RESISTANCE; EXPERIMENTAL THERAPY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HISTONE CODE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; NEOPLASMS; PROTEIN PROCESSING;

ANTINEOPLASTIC AGENT; CHROMATIN; DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; ONCOPROTEIN; TUMOR PROTEIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; CHROMOSOME ABERRATIONS; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE CODE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MICE; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; THERAPIES, INVESTIGATIONAL; TRANSCRIPTION, GENETIC;

EID: 84962688557     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.007     Document Type: Review

References (148)

1. Alekseyenko A.A., Walsh E.M., Wang X., Grayson A.R., Hsi P.T., Kharchenko P.V., Kuroda M.I., French C.A. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev. 2015, 29:1507-1523.
2. Andersson A.K., Ma J., Wang J., Chen X., Gedman A.L., Dang J., Nakitandwe J., Holmfeldt L., Parker M., Easton J., et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 2015, 47:330-337.
3. Antonysamy S., Condon B., Druzina Z., Bonanno J.B., Gheyi T., Zhang F., MacEwan I., Zhang A., Ashok S., Rodgers L., et al. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS One 2013, 8:1-15.
4. Asangani I.A., Dommeti V.L., Wang X., Malik R., Cieslik M., Yang R., Escara-Wilke J., Wilder-Romans K., Dhanireddy S., Engelke C., et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014, 510:278-282.
5. Azuma K., Tsurutani J., Sakai K., Kaneda H., Fujisaka Y., Takeda M., Watatani M., Arao T., Satoh T., Okamoto I., et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem. Biophys. Res. Commun. 2011, 407:219-224.
6. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nucleus 2011, 11:726-734.
7. Béguelin W., Popovic R., Teater M., Jiang Y., Bunting K.L., Rosen M., Shen H., Yang S.N., Wang L., Ezponda T., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23:677-692.
8. Bernstein B.E., Stamatoyannopoulos J.A., Costello J.F., Ren B., Milosavljevic A., Meissner A., Kellis M., Marra M.A., Beaudet A.L., Ecker J.R., et al. The NIH roadmap epigenomics mapping consortium. Nat. Biotechnol. 2010, 28:1045-1048.
9. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
10. Brien G.L., Bracken A.P. Transcriptomics: unravelling the biology of transcription factors and chromatin remodelers during development and differentiation. Semin. Cell Dev. Biol. 2009, 20:835-841.
11. Britschgi A., Andraos R., Brinkhaus H., Klebba I., Romanet V., Müller U., Murakami M., Radimerski T., Bentires-Alj M. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22:796-811.
12. Britton L.-M.P., Gonzales-Cope M., Zee B.M., Garcia B.A. Breaking the histone code with quantitative mass spectrometry. Expert Rev. Proteomics 2011, 8:631-643.
13. Brown R., Curry E., Magnani L., Wilhelm-Benartzi C.S., Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat. Rev. Cancer 2014, 14:747-753.
14. Cai S.F., Chen C.-W., Armstrong S.A. Drugging chromatin in cancer: recent advances and novel approaches. Mol. Cell 2015, 60:561-570.
15. Cain C. NSD2 momentum. Sci. Exch. 2013, 6. 10.1038/scibx.2013.1083.
16. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
17. Chen C.-W., Koche R.P., Sinha A.U., Deshpande A.J., Zhu N., Eng R., Doench J.G., Xu H., Chu S.H., Qi J., et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 2015, 21:1-10.
18. Chesi M., Nardini E., Lim R.S., Smith K.D., Kuehl W.M., Bergsagel P.L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998, 92:3025-3034.
19. Chipumuro E., Marco E., Christensen C.L., Kwiatkowski N., Zhang T., Hatheway C.M., Abraham B.J., Sharma B., Yeung C., Altabef A., et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 2014, 159:1126-1139.
20. Christensen C.L., Kwiatkowski N., Abraham B.J., Carretero J., Al-Shahrour F., Zhang T., Chipumuro E., Herter-Sprie G.S., Akbay E.A., Altabef A., et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 2014, 26:909-922.
21. Conway E., Healy E., Bracken A.P. PRC2 mediated H3K27 methylations in cellular identity and cancer. Curr. Opin. Cell Biol. 2015, 37:42-48.
22. Coolen M.W., Stirzaker C., Song J.Z., Statham A.L., Kassir Z., Moreno C.S., Young A.N., Varma V., Speed T.P., Cowley M., et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat. Cell Biol. 2010, 12:235-246.
23. Creech A.L., Taylor J.E., Maier V.K., Wu X., Feeney C.M., Udeshi N.D., Peach S.E., Boehm J.S., Lee J.T., Carr S.A., et al. Building the connectivity map of epigenetics: chromatin profiling by quantitative targeted mass spectrometry. Methods 2014, 72:57-64.
24. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., Johnston L.D., Scott M.P., Smith J.J., Xiao Y., Jin L. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
25. Daigle S.R., Olhava E.J., Therkelsen C.A., Basavapathruni A., Jin L., Boriack-Sjodin P.A., Allain C.J., Klaus C.R., Raimondi A., Scott M.P., Waters N.J. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
26. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.-I., Robson S.C., Chung C., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
27. De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014, 514:247-251.
28. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
29. Deshpande A.J., Bradner J., Armstrong S.A. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012, 33:563-570.
30. Djabali M., Selleri L., Parry P., Bower M., Young B.D., Evans G.A. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat. Genet. 1992, 2:113-118.
31. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
32. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13:673-691.
33. Feinberg A.P., Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 1983, 111:47-54.
34. Ferrari K.J., Scelfo A., Jammula S., Cuomo A., Barozzi I., Stützer A., Fischle W., Bonaldi T., Pasini D. Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity. Mol. Cell 2014, 53:49-62.
35. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
36. Fillmore C.M., Xu C., Desai P.T., Berry J.M., Rowbotham S.P., Lin Y.-J., Zhang H., Marquez V.E., Hammerman P.S., Wong K.-K., Kim C.F. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 2015, 520:239-242.
37. Fiskus W., Sharma S., Shah B., Portier B.P., Devaraj S.G.T., Liu K., Iyer S.P., Bearss D., Bhalla K.N. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014, 28:2155-2164.
38. Fong C.Y., Gilan O., Lam E.Y.N., Rubin A.F., Ftouni S., Tyler D., Stanley K., Sinha D., Yeh P., Morison J., et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 2015, 525:538.
39. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
40. French C.A. NUT midline carcinoma. Nat. Rev. Cancer 2014, 14:149-150.
41. French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J., Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R., et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 2008, 27:2237-2242.
42. French C.A., Rahman S., Walsh E.M., Kühnle S., Grayson A.R., Lemieux M.E., Grunfeld N., Rubin B.P., Antonescu C.R., Zhang S., et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014, 4:929-941.
43. Frigola J., Song J., Stirzaker C., Hinshelwood R.A., Peinado M.A., Clark S.J. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 2006, 38:540-549.
44. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
45. Gibaja V., Shen F., Harari J., Korn J., Ruddy D., Saenz-Vash V., Zhai H., Rejtar T., Paris C.G., Yu Z., et al. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 2015, 35:1-9.
46. Grayson A.R., Walsh E.M., Cameron M.J., Godec J., Ashworth T., Ambrose J.M., Aserlind A.B., Wang H., Evan G.I., Kluk M.J., et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 2014, 33:1736-1742.
47. Greaves M. Infant leukaemia biology, aetiology and treatment. Leukemia 1996, 10:372-377.
48. Greger V., Passarge E., Höpping W., Messmer E., Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 1989, 83:155-158.
49. Gu Y., Nakamura T., Alder H., Prasad R., Canaani O., Cimino G., Croce C.M., Canaani E. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992, 71:701-708.
50. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
51. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
52. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A.J., et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574-586.
53. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13:714-726.
54. Huang Z., Wu H., Chuai S., Xu F., Yan F., Englund N., Wang Z., Zhang H., Fang M., Wang Y., et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res. 2013, 73:6277-6288.
55. Issa J.-P.J., Kantarjian H.M. Targeting DNA methylation. Clin. Cancer Res. 2009, 15:3938-3946.
56. Jaffe J.D., Wang Y., Chan H.M., Zhang J., Huether R., Kryukov G.V., Bhang H.C., Taylor J.E., Hu M., Englund N.P., et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 2013, 45:1386-1391.
57. Jang M.K., Mochizuki K., Zhou M., Jeong H.-S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
58. Jiang Y.W., Veschambre P., Erdjument-Bromage H., Tempst P., Conaway J.W., Conaway R.C., Kornberg R.D. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc. Natl. Acad. Sci. USA 1998, 95:8538-8543.
59. Jo S.Y., Granowicz E.M., Maillard I., Thomas D., Hess J.L. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011, 117:4759-4768.
60. Kadoch C., Crabtree G.R. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 2015, 1:e1500447.
61. Kadoch C., Hargreaves D.C., Hodges C., Elias L., Ho L., Ranish J., Crabtree G.R. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 2013, 45:592-601.
62. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66:11341-11347.
63. Kauffman E.C., Robinson B.D., Downes M.J., Powell L.G., Lee M.M., Scherr D.S., Gudas L.J., Mongan N.P. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 2011, 50:931-944.
64. Keats J.J., Reiman T., Maxwell C.A., Taylor B.J., Larratt L.M., Mant M.J., Belch A.R., Pilarski L.M. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
65. Kennison J.A., Tamkun J.W. Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila. Proc. Natl. Acad. Sci. USA 1988, 85:8136-8140.
66. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90:85-94.
67. Kia S.K., Gorski M.M., Giannakopoulos S., Verrijzer C.P. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell Biol. 2008, 28:3457-3464.
68. Kim K.H., Kim W., Howard T.P., Vazquez F., Tsherniak A., Wu J.N., Wang W., Haswell J.R., Walensky L.D., Hahn W.C., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 2015, 21:1491-1497.
69. Knoechel B., Roderick J.E., Williamson K.E., Zhu J., Lohr J.G., Cotton M.J., Gillespie S.M., Fernandez D., Ku M., Wang H., et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 2014, 46:364-370.
70. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 2012, 8:890-896.
71. Knutson S.K., Warholic N.M., Wigle T.J., Klaus C.R., Allain C.J., Raimondi A., Porter Scott M., Chesworth R., Moyer M.P., Copeland R.A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 2013, 110:7922-7927.
72. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
73. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
74. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
75. Kuo A.J., Cheung P., Chen K., Zee B.M., Kioi M., Lauring J., Xi Y., Park B.H., Shi X., Garcia B.A., et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 2011, 44:609-620.
76. Kwiatkowski N., Zhang T., Rahl P.B., Abraham B.J., Reddy J., Ficarro S.B., Dastur A., Amzallag A., Ramaswamy S., Tesar B., et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014, 511:616-620.
77. Larochelle S., Amat R., Glover-Cutter K., Sansó M., Zhang C., Allen J.J., Shokat K.M., Bentley D.L., Fisher R.P. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol. 2012, 19:1108-1115.
78. Laubach J.P., Moreau P., San-Miguel J.F., Richardson P.G. Panobinostat for the treatment of multiple myeloma. Clin. Cancer Res. 2015, 21:4767-4774.
79. Lee W., Teckie S., Wiesner T., Ran L., Prieto Granada C.N., Lin M., Zhu S., Cao Z., Liang Y., Sboner A., et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 2014, 46:1227-1232.
80. Lee H., Kahn T.G., Simcox A., Schwartz Y.B., Pirrotta V. Genome-wide activities of Polycomb complexes control pervasive transcription. Genome Res. 2015, 25:1170-1181.
81. Lin C.Y., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
82. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
83. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
84. Mansour M.R., Abraham B.J., Anders L., Gutierrez A., Durbin A.D., Lawton L., Sallan S.E., Silverman L.B., Loh M.L., Hunger S.P., et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014, 346:1373-1377.
85. Marango J., Shimoyama M., Nishio H., Meyer J.A., Min D.-J., Sirulnik A., Martinez-Martinez Y., Chesi M., Bergsagel P.L., Zhou M.-M., et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008, 111:3145-3154.
86. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
87. Mazur P.K., Herner A., Mello S.S., Wirth M., Hausmann S., Sánchez-Rivera F.J., Lofgren S.M., Kuschma T., Hahn S.A., Vangala D., et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 2015, 21:1163-1171.
88. McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y., Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., Chen S.B. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 2012, 109:2989-2994.
89. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Della Pietra A., Diaz E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
90. Metzger E., Wissmann M., Yin N., Müller J.M., Schneider R., Peters A.H.F.M., Günther T., Buettner R., Schüle R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437:436-439.
91. Mishra B.P., Zaffuto K.M., Artinger E.L., Org T., Mikkola H.K.A., Cheng C., Djabali M., Ernst P. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep. 2014, 7:1239-1247.
92. Mohammad H., Smitheman K., Kamat C., Soong D., Federowicz K., VanAller G., Schneck J., Carson J., Liu Y., Butticello M., et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 2015, 28:57-69.
93. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
94. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
95. Muntean A.G., Hess J.L. The pathogenesis of mixed-lineage leukemia. Annu. Rev. Pathol. Mech. Dis. 2012, 7:283-301.
96. Nguyen A.T., Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011, 25:1345-1358.
97. Nguyen A.T., Taranova O., He J., Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011, 117:6912-6922.
98. Nikoloski G., Langemeijer S.M.C., Kuiper R.P., Knops R., Massop M., Tönnissen E.R.L.T.M., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
99. Nimura K., Ura K., Shiratori H., Ikawa M., Okabe M., Schwartz R.J., Kaneda Y. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009, 460:287-291.
100. Nogales E. The development of cryo-EM into a mainstream structural biology technique. Nat. Methods 2016, 13:24-27.
101. Ntziachristos P., Tsirigos A., Van Vlierberghe P., Nedjic J., Trimarchi T., Flaherty M.S., Ferres-Marco D., da Ros V., Tang Z., Siegle J., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 2012, 18:298-303.
102. Oldridge D.A., Wood A.C., Weichert-Leahey N., Crimmins I., Sussman R., Winter C., McDaniel L.D., Diamond M., Hart L.S., Zhu S., et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 2015, 528:418-421.
103. Oyer J.A., Huang X., Zheng Y., Shim J., Ezponda T., Carpenter Z., Allegretta M., Okot-Kotber C.I., Patel J.P., Melnick A., et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltransferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia 2014, 28:198-201.
104. Palomero T., Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin. Lymphoma Myeloma 2009, 9(Suppl 3):S205-S210.
105. Pasini D., Malatesta M., Jung H.R., Walfridsson J., Willer A., Olsson L., Skotte J., Wutz A., Porse B., Jensen O.N., Helin K. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 2010, 38:4958-4969.
106. Popovic R., Martinez-Garcia E., Giannopoulou E.G., Zhang Q., Zhang Q., Ezponda T., Shah M.Y., Zheng Y., Will C.M., Small E.C., et al. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet. 2014, 10:e1004566.
107. Qi W., Chan H., Teng L., Li L., Chuai S., Zhang R., Zeng J., Li M., Fan H. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. USA 2012, 109:21360-21365.
108. Rathert P., Roth M., Neumann T., Muerdter F., Roe J.-S., Muhar M., Deswal S., Cerny-Reiterer S., Peter B., Jude J., et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 2015, 525:543-547.
109. Rexer B.N., Ham A.-J.L., Rinehart C., Hill S., Granja-Ingram N.D.M., González-Angulo A.M., Mills G.B., Dave B., Chang J.C., Liebler D.C., Arteaga C.L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
110. Reynoird N., Schwartz B.E., Delvecchio M., Sadoul K., Meyers D., Mukherjee C., Caron C., Kimura H., Rousseaux S., Cole P.A., et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010, 29:2943-2952.
111. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 1991, 48:880-888.
112. Santra M., Zhan F., Tian E., Barlogie B., Shaughnessy J. Brief report. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003, 101:2374-2376.
113. Schenk T., Chen W.C., Göllner S., Howell L., Jin L., Hebestreit K., Klein H.-U., Popescu A.C., Burnett A., Mills K., Casero R.A. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 2012, 18:605-611.
114. Schmitges F.W., Prusty A.B., Faty M., Stutzer A., Lingaraju G.M., Aiwazian J., Sack R., Hess D., Li L., Zhou S., et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol. Cell 2011, 42:330-341.
115. Schulte J.H., Lim S., Schramm A., Friedrichs N., Koster J., Versteeg R., Ora I., Pajtler K., Klein-Hitpass L., Kuhfittig-Kulle S., Metzger E. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009, 69:2065-2071.
116. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
117. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
118. Shen C., Ipsaro J.J., Shi J., Milazzo J.P., Wang E., Roe J.-S., Suzuki Y., Pappin D.J., Joshua-Tor L., Vakoc C.R. NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Mol. Cell 2015, 60:847-859.
119. Shi J., Vakoc C.R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 2014, 54:728-736.
120. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
121. Shi J., Wang E., Milazzo J.P., Wang Z., Kinney J.B., Vakoc C.R. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 2015, 33:1-10.
122. Shu S., Lin C.Y., He H.H., Witwicki R.M., Tabassum D.P., Roberts J.M., Janiszewska M., Jin Huh S., Liang Y., Ryan J., et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 2016, 529:1-24.
123. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 2010, 107:20980-20985.
124. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
125. Stratikopoulos E.E., Dendy M., Szabolcs M., Khaykin A.J., Lefebvre C., Zhou M.-M., Parsons R. Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy. Cancer Cell 2015, 27:837-851.
126. Stuhlmiller T.J., Miller S.M., Zawistowski J.S., Nakamura K., Beltran A.S., Duncan J.S., Angus S.P., Collins K.A.L., Granger D.A., Reuther R.A., et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 2015, 11:390-404.
127. Stunnenberg H.G., Vermeulen M. Towards cracking the epigenetic code using a combination of high-throughput epigenomics and quantitative mass spectrometry-based proteomics. Bioessays 2011, 33:547-551.
128. Tamkun J.W., Deuring R., Scott M.P., Kissinger M., Pattatucci A.M., Kaufman T.C., Kennison J.A. brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 1992, 68:561-572.
129. Tessarz P., Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 2014, 15:703-708.
130. Tkachuk D.C., Kohler S., Cleary M.L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992, 71:691-700.
131. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
132. Wagner J.M., Hackanson B., Lübbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 2010, 1:117-136.
133. Wang R., You J. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation. J. Biol. Chem. 2015, 290:2744-2758.
134. Wang Y., Zhang T., Kwiatkowski N., Young R.A., Gray N.S., Zhao J.J., Lee T.I., Xie S., Yuzugullu H., Abraham B.J., et al. CDK7-Dependent transcriptional addiction in triple-negative breast cancer article CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 2015, 163:174-186.
135. Watson P.A., Arora V.K., Sawyers C.L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 2015, 15:701-711.
136. Wigle T.J., Knutson S.K., Jin L., Kuntz K.W., Pollock R.M., Richon V.M., Copeland R.A., Scott M.P. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 2011, 585:3011-3014.
137. Wilson B.G., Wang X., Shen X., McKenna E.S., Lemieux M.E., Cho Y.-J., Koellhoffer E.C., Pomeroy S.L., Orkin S.H., Roberts C.W.M. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010, 18:316-328.
138. Winter G.E., Buckley D.L., Paulk J., Roberts J.M., Souza A., Dhe-Paganon S., Bradner J.E. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 2015, 348:1376-1381.
139. Wong S.H.K., Goode D.L., Iwasaki M., Wei M.C., Kuo H.P., Zhu L., Schneidawind D., Duque-Afonso J., Weng Z., Cleary M.L. The H3K4-methyl epigenome regulates leukemia stem cell oncogenic potential. Cancer Cell 2015, 28:198-209.
140. Yang Z., Yik J.H.N., Chen R., He N., Jang M.K., Ozato K., Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
141. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., Morin R.D., Mungall A.J., Meissner B., Boyle M., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
142. Yashiro-Ohtani Y., Wang H., Zang C., Arnett K.L., Bailis W., Ho Y., Knoechel B., Lanauze C., Louis L., Forsyth K.S., et al. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc. Natl. Acad. Sci. USA 2014, 111:E4946-E4953.
143. Yuan W., Xu M., Huang C., Liu N., Chen S., Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J. Biol. Chem. 2011, 286:7983-7989.
144. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., Easton J., Chen X., Wang J., Rusch M., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
145. Zhang M., Wang Y., Jones S., Sausen M., McMahon K., Sharma R., Wang Q., Belzberg A.J., Chaichana K., Gallia G.L., et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 2014, 46:1170-1172.
146. Zhou Q., Li T., Price D.H. RNA polymerase II elongation control. Annu. Rev. Biochem. 2012, 81:119-143.
147. Ziemin-van der Poel S., McCabe N.R., Gill H.J., Espinosa R., Patel Y., Harden A., Rubinelli P., Smith S.D., LeBeau M.M., Rowley J.D. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl. Acad. Sci. USA 1991, 88:10735-10739.
148. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.